Statoil ASA: Notifiable trading

Dec 11, 2017 06:26 am UTC| Business

On behalf of Statoil (OSE: STL, NYSE:STO), DNB has on 8 Desember 2017 purchased 512,546 shares for use in the group's Share saving plan. The shares have been acquired at a price of NOK 166.85 per share. Before...

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

Dec 11, 2017 06:06 am UTC| Business

Workshop to be held on Monday, December 11th at 12:00 pm EST December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep...

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Dec 11, 2017 06:01 am UTC| Business

Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the...

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Dec 11, 2017 06:01 am UTC| Business

Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study 75% of ARGX-113 treated patients had a...

Global Identity and Access Management Market Will Reach USD 15.92 Billion by 2022: Zion Market Research

Dec 11, 2017 05:56 am UTC| Business

Sarasota, FL, Dec. 11, 2017 -- Zion Market Research has published a new report titled “Identity and Access Management Market by Component (Provisioning, Single Sign-On, Advanced Authentication, Audit, Compliance ...

ThalesNano launches low pressure version of its H-Cube Mini Plus bench top hydrogenation reactor

Dec 10, 2017 23:10 pm UTC| Business

BUDAPEST, Hungary, Dec. 10, 2017 -- The ThalesNano H-Cube family members have revolutionized the way research chemists can make hydrogenation reactions by simplifying the process through the use of flow chemistry...

Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting

Dec 10, 2017 23:05 pm UTC| Business

− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma – − Expanding Program to Include Colorectal Cancer, Castration-resistant Prostate Cancer, and...